This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Luteinising hormone releasing hormone agonists (also called gonadotropin-releasing hormone agonists GnRH agonists) are agents used in the hormonal modulation of malignant and benign diseases including:

  • prostatic carcinoma
  • breast carcinoma
  • endometriosis

These agents may cause an initial stimulation in the secretion of luteinising hormone (LH) resulting in a "flare" in symptoms in patients with symptomatic prostatic cancer during the first 1-2 weeks of treatment.

After 1-2 weeks pituitary gonadotrophin secretion is down-regulated leading to inhibition of ovarian and testicular sex hormone production.

If a tumour flare is likely to cause problems e.g. spinal cord compression, then an antiandrogen should also be given at least 3 days before the LHRH agonist and continued concurrently for three weeks.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page